Quantcast

Latest Cancer treatments Stories

2014-09-02 08:30:12

Kyungpook National University Hospital in South Korea Treats the First Patient in the 14 Country, 100 Site Global Study LAWRENCEVILLE, N.J., Sept. 2, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) in patients with primary liver cancer, also known as hepatocellular...

2014-09-02 08:29:06

TORONTO AND CHICAGO, Sept. 2, 2014 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia") (TSX:CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc. ("Pinnacle"), a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN(®) (porfimer sodium)...

2014-08-27 23:02:42

NovoTTF™-100A System Offers Novel, Non-Invasive Treatment in Fight Against an Aggressive Type of Brain Cancer Morristown,NJ (PRWEB) August 27, 2014 ANS is pleased to announce the availability of NovoTTF-100A System, a ground breaking anti-cancer therapy for the treatment of recurrent glioblastoma (GBM). Experts at ANS are now certified to prescribe this new medical therapy and will begin extending this new treatment option for recurrent GBM patients starting immediately. NovoTTF™...

2014-08-19 12:28:17

SYDNEY, Aug. 19, 2014 /PRNewswire/ -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ("Prima", the "Company") today announced that the abstract entitled, "Trial evaluating overall survival in epithelial ovarian cancer (EOC) patients in second remission with an autologous dendritic cell therapy targeting mucin 1" has been accepted for a poster presentation at the Society for Immunotherapy of Cancer ("SITC") 29th Annual Meeting. The poster will be presented by Prima's...

2014-08-18 16:28:13

WASHINGTON, Aug. 18, 2014 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) President & CEO, Laurie Fenton Ambrose praised the National Cancer Institute's (NCI) new trial, launched today, that will focus on the prevention of recurrence in two specific types of lung cancers when they are caught at early stage and surgically removed. "This trial demonstrates the power of CT screening to open new research windows on critical problems, such as recurrence, that have eluded...

2014-08-14 08:30:20

Company Strengthens Intellectual Property Protection in Additional Global Market DALLAS and NEW YORK, Aug. 14, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the Japan Patent Office that a patent for MuGard and ProctiGard has been granted. The patent covers a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders. "Following our recent European...

venom fights cancer
2014-08-13 05:35:26

redOrbit Staff & Wire Reports - Your Universe Online Bee stings and snake bites are not typically viewed as things that are beneficial to a person’s health, but new research out of the University of Illinois suggests that they could be powerful tools in the treatment of cancer. [ Watch: Treating Cancer With Venom ] In research presented at the 248th National Meeting of the American Chemical Society (ACS) in San Francisco, California on Monday, Dr. Dipanjan Pan described how...

2014-08-11 08:29:09

Patented Technology Enables Accurate Delivery of a Chemotherapeutic Drug to Targeted Tumor Cells, Reducing Drug-related Toxicity without Sacrificing Therapeutic Impact SYDNEY, Aug. 11, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No....

2014-08-11 08:28:38

TORONTO, ON and CHICAGO, IL, Aug. 11, 2014 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, enrolled the first patients in a randomized Phase 2 trial to evaluate...

2014-08-11 08:28:16

TAMPA, Fla., Aug. 11, 2014 /PRNewswire/ -- Morphogenesis Inc., the Tampa-based biotech company that developed the ImmuneFx(TM) cancer vaccine for dogs, cats and horses, announces that it has chosen Florida Veterinary Referral Center & 24-Hour Emergency Hospital in Estero, FL, as the newest exclusive provider of the ImmuneFx(TM) therapy process for companion animals. ImmuneFx(TM) primes and educates the pet's own immune system to recognize and kill cancer cells without harming...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'